World Health Organization Sounds Warning Over Critical Lack of Weight-Loss Jabs
Under a tenth of individuals that would benefit from obesity jabs including Wegovy are able to get them, caution the global health agency as it releases its inaugural guidance on the therapies.
Considering more than one billion individuals worldwide currently obese, it is calling for broader and more equitable access to this class of drugs.
Per projections, more than two billion are projected to be obese by 2030 if no action is taken.
"The new guidelines affirms that excess weight is a chronic disease that can be addressed with comprehensive and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are significant barriers to widespread availability to the treatments that can aid individuals in losing substantial weight, explains the organization.
Skinny Jab Supply Crisis
Even in the present best projected case, the supply of GLP-1 therapies might only reach about 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The advice calls on governments and firms to expand availability, through measures such as licensing agreements.
A patent on the active ingredient – the main ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Jabs Work
GLP-1 drugs mimick a body's own hormone to reduce digestion speed, suppress the appetite and enhance satiety so individuals eat less.
People typically see weight reduction in the initial weeks of beginning the regular doses.
Evidence indicates people may put most of the weight back on after a year of halting the drug, as their usual hunger resume.
Being overweight or obese increases your risk for developing diseases, including diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight concerns people in every country and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.
